Impact of genotype-predicted CYP2D6 metabolism on clinical effects and tolerability of metoprolol in patients after myocardial infarction - a prospective observational study.
Anne Kristine AnstensrudEspen MoldenHans Jørgen HaugRehman QaziHysen MuriqLinn E FosshaugOlav SpigsetErik ØiePublished in: European journal of clinical pharmacology (2020)
Using a comprehensive CYP2D6 genotyping panel, the present study demonstrates a > 6-fold increase of dose-adjusted plasma metoprolol trough concentration in CYP2D6 PMs vs. EMs with a parallel lower increase in achieved maximum HR during exercise but without association between genotype and frequency or severity of self-reported adverse drug effects. This may indicate that CYP2D6 PMs potentially could benefit of the increased plasma concentration per dose in a naturalistic setting.
Keyphrases
- adverse drug
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- emergency department
- prognostic factors
- high throughput
- randomized controlled trial
- high intensity
- open label
- gene expression
- dna methylation
- resistance training
- electronic health record
- cross sectional
- single cell
- drug induced
- placebo controlled